Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis

Status Completed

Clinical Trial Summary

This study will treat subjects with complicated VVC who have failed prior fluconazole therapy with Ibrexafungerp for 1, 3 or 7 days of treatment.

Clinical Trial Description

This study will treat subjects with complicated VVC who have failed prior fluconazole therapy with Ibrexafungerp for 1, 3 or 7 days of treatment. Approximately 150 eligible subjects will be enrolled. Subjects will be randomized to receive oral ibrexafungerp 300 mg administered twice a day (BID) for either one, three, or seven consecutive days, stratified by group based on Candida species and presence or absence of underlying medical conditions. The primary endpoint for this study is the percentage of subjects with a clinical cure at the Test of Cure Visit. Test of Cure is defined as a score of zero on the Vulvovaginal Signs and Symptoms Scale and not requiring additional antifungal treatment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05399641
Study type	Interventional
Source	Scynexis, Inc.
Contact
Status	Completed
Phase	Phase 3
Start date	May 1, 2022
Completion date	August 2, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05012852` - Evaluation of VagiVitalAC for Treatment of Candida Vulvovaginitis	N/A
Completed	`NCT02150655` - Study of the Microbiota, Metabolome, and Environmental Toxins in Relation to Reproductive Health in Rwandan Women	Phase 0
Completed	`NCT00755053` - Comparative Efficacy of Ovule vs Tablet	Phase 3
Completed	`NCT02679456` - Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis	Phase 2
Completed	`NCT02242695` - Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis	Phase 4
Not yet recruiting	`NCT05079711` - Comparative Performance of a Vaginal Yeast Test
Completed	`NCT00895453` - Monthly Itraconazole Versus Classic Homeopathy for Treatment of Recurrent Vulvovaginal Candidiasis (RVVC)	N/A
Completed	`NCT05327192` - VVC Sampling Study for Analysis Validation
Completed	`NCT01806623` - The Study Of Fluconazole For Vulvovaginal Candidiasis	Phase 3
Completed	`NCT05507333` - Clinical Performance of the Gedea Pessary in Adult Women With Vulvovaginal Candidiasis	N/A
Completed	`NCT01144286` - Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment	Phase 2
Completed	`NCT00353561` - Diabetes Mellitus and Vulvovaginal Candidiasis	Phase 3
Recruiting	`NCT05895162` - Zinc-containing Vaginal Gel and Oral Fluconazole for Vulvovaginal Candidiasis.	N/A
Recruiting	`NCT05908682` - Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes
Completed	`NCT02203942` - Comparing NAAT Testing to Standard Methods for the Diagnosis of Vaginitis	N/A
Completed	`NCT01926028` - Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis	Phase 1/Phase 2
Completed	`NCT00194324` - Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina	Phase 4
Completed	`NCT02866227` - TOL-463 Phase 2 Study for Vaginitis	Phase 2
Withdrawn	`NCT05031481` - Efficacy and Safety of Different Doses of Venus Association in Patients With Vulvovaginal Candidiasis.	Phase 2
Completed	`NCT03761628` - Clinical Performance of a Vaginal Pessary (pHyph) in Vulvovaginal Candidiasis	N/A